Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars To Be Subject To Same Pay-For-Delay Deal Reporting As Generics

Executive Summary

Legislation headed to President Trump would also ban pharmacy "gag" clauses.

You may also be interested in...



Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?

AbbVie's Humira settlements suggest issues that FTC will be scrutinizing, such as biosimilar entry date, royalty payments, and acceleration clauses.

Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?

AbbVie's Humira settlements suggest issues that FTC will be scrutinizing, such as biosimilar entry date, royalty payments, and acceleration clauses.

Pharmacy “Gag Clause” Bills: Another Simple Fix For Drug Pricing That Is Not So Simple

US Congress wants to prohibit contracts that prevent pharmacists from alerting customers to opportunities to save money by paying out of pocket. Legislation is moving rapidly, but once again, a simple fix to a drug pricing issue may have unintended consequences.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel